Terms: = Liver cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568
691 results:
1. A novel engineered il-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma.
Zhu W; Zhang Z; Chen J; Chen X; Huang L; Zhang X; Huang X; Ma N; Xu W; Yi X; Lu X; Fu X; Li S; Mo G; Wang Y; Yuan G; Zang M; Li Q; Jiang X; He Y; Wu S; He Y; Li Y; Hou J
Signal Transduct Target Ther; 2024 Apr; 9(1):101. PubMed ID: 38643203
[TBL] [Abstract] [Full Text] [Related]
2. Deep phenotyping of dementia in a multi-ethnic cardiovascular cohort: The Multi-Ethnic Study of Atherosclerosis (MESA).
Ostovaneh MR; Hughes TM; Wu CO; McClelland RL; Casanova R; Bluemke DA; Tracy RP; Shea S; Heckbert SR; Lima JAC; Ambale-Venkatesh B
PLoS One; 2024; 19(4):e0298952. PubMed ID: 38635767
[TBL] [Abstract] [Full Text] [Related]
3. il-2-mediated hepatotoxicity: knowledge gap identification based on the irAOP concept.
Roser LA; Sakellariou C; Lindstedt M; Neuhaus V; Dehmel S; Sommer C; Raasch M; Flandre T; Roesener S; Hewitt P; Parnham MJ; Sewald K; Schiffmann S
J Immunotoxicol; 2024 Dec; 21(1):2332177. PubMed ID: 38578203
[TBL] [Abstract] [Full Text] [Related]
4. Tumor-activated il-2 mRNA delivered by lipid nanoparticles for cancer immunotherapy.
Jiang Y; Zhang Y; Liu C; Liu J; Xue W; Wang Z; Li X
J Control Release; 2024 Apr; 368():663-675. PubMed ID: 38492862
[TBL] [Abstract] [Full Text] [Related]
5. Improvement of hepatic innate immunity in chemically-injured livers to develop hepatocarcinoma by a serine type-protease inhibitors enriched extract from
Rueda Huélamo MA; Martínez Perlado A; Consoli V; García-Tejedor A; Haros CM; Laparra Llopis JM
Food Funct; 2024 Apr; 15(7):3600-3614. PubMed ID: 38469889
[TBL] [Abstract] [Full Text] [Related]
6. Enhanced NK cell activation via eEF2K-mediated potentiation of the cGAS-STING pathway in hepatocellular carcinoma.
Xu Y; Sun F; Tian Y; Zeng G; Lei G; Bai Z; Wang Y; Ge X; Wang J; Xiao C; Wang Z; Hu M; Song J; Yang P; Liu R
Int Immunopharmacol; 2024 Mar; 129():111628. PubMed ID: 38320351
[TBL] [Abstract] [Full Text] [Related]
7. Generation and assessment of cytokine-induced killer cells for the treatment of colorectal cancer liver metastases.
Li CMY; Tomita Y; Dhakal B; Tin T; Li R; Wright JA; Vrbanac L; Woods SL; Drew P; Price T; Smith E; Maddern GJ; Fenix K
Cancer Immunol Immunother; 2024 Jan; 73(1):6. PubMed ID: 38231291
[TBL] [Abstract] [Full Text] [Related]
8. il-2 produced by HBV-specific T cells as a biomarker of viral control and predictor of response to PD-1 therapy across clinical phases of chronic hepatitis B.
Chua C; Salimzadeh L; Ma AT; Adeyi OA; Seo H; Boukhaled GM; Mehrotra A; Patel A; Ferrando-Martinez S; Robbins SH; La D; Wong D; Janssen HLA; Brooks DG; Feld JJ; Gehring AJ
Hepatol Commun; 2023 Dec; 7(12):. PubMed ID: 38055623
[TBL] [Abstract] [Full Text] [Related]
9. Clinical Effect of the Combination of Compound Kushen Injection and Gemcitabine on Postoperative Patients with Non-Muscle Invasive Bladder cancer and Its Influence on Serum-Related Factors.
Dong X; Wang Y; Wang S; Li C; Zhang M; Hou F
Arch Esp Urol; 2023 Nov; 76(9):657-665. PubMed ID: 38053420
[TBL] [Abstract] [Full Text] [Related]
10. Mechanism Research and Application for Ginsenosides in the Treatment of Hepatocellular Carcinoma.
Zhou N; Mao F; Cheng S
Biomed Res Int; 2023; 2023():7214037. PubMed ID: 38027042
[TBL] [Abstract] [Full Text] [Related]
11. Targeting regulatory T cells by E7777 enhances CD8 T-cell-mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models.
Mahdi HS; Woodall-Jappe M; Singh P; Czuczman MS
Front Immunol; 2023; 14():1268979. PubMed ID: 38022532
[TBL] [Abstract] [Full Text] [Related]
12. Characterizing hepatocellular carcinoma stem markers and their corresponding susceptibility to NK-cell based immunotherapy.
Chiang J; Chen PC; Pham J; Nguyen CQ; Kaur K; Raman SS; Jewett A
Front Immunol; 2023; 14():1284669. PubMed ID: 37954598
[TBL] [Abstract] [Full Text] [Related]
13. Risk assessment of cancer patients based on HLA-I alleles, neobinders and expression of cytokines.
Dhall A; Patiyal S; Kaur H; Raghava GPS
Comput Biol Med; 2023 Dec; 167():107594. PubMed ID: 37918263
[TBL] [Abstract] [Full Text] [Related]
14. Establishment and validation of a novel lysosome-related gene signature for predicting prognosis and immune landscape in hepatocellular carcinoma.
Li H; Li J; Qu X; Dai H; Liu J; Ma M; Wang J; Dong W; Wang W
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17543-17557. PubMed ID: 37903936
[TBL] [Abstract] [Full Text] [Related]
15. The Protective Effects of Water-Soluble Alginic Acid on the N-Terminal of Thymopentin.
Ji H; Fan Y; Gao X; Gong Y; Dai K; Wang Z; Xu B; Yu J
Molecules; 2023 Sep; 28(18):. PubMed ID: 37764221
[TBL] [Abstract] [Full Text] [Related]
16. Discovery of potent and selective HPK1 inhibitors based on the 2,4-disubstituted pyrimidine scaffold with immune modulatory properties for ameliorating T cell exhaustion.
Zeng S; Zeng M; Yuan S; He L; Jin Y; Huang J; Zhang M; Yang M; Pan Y; Wang Z; Chen Y; Xu X; Huang W
Bioorg Chem; 2023 Oct; 139():106728. PubMed ID: 37536217
[TBL] [Abstract] [Full Text] [Related]
17. Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers.
Borcoman E; Lalanne A; Delord JP; Cassier PA; Rolland F; Salas S; Limacher JM; Capitain O; Lantz O; Ekwegbara C; Jeannot E; Cyrta J; Tran-Perennou C; Castel-Ajgal Z; Marret G; Piaggio E; Brandely M; Tavernaro A; Makhloufi H; Bendjama K; Le Tourneau C
Eur J Cancer; 2023 Sep; 191():112981. PubMed ID: 37506588
[TBL] [Abstract] [Full Text] [Related]
18. Magnetic-Manipulated NK Cell Proliferation and Activation Enhance Immunotherapy of Orthotopic liver cancer.
Jiang H; Fu H; Min T; Hu P; Shi J
J Am Chem Soc; 2023 Jun; 145(24):13147-13160. PubMed ID: 37262421
[TBL] [Abstract] [Full Text] [Related]
19. Network Toxicology Prediction and Molecular Docking-based Strategy to Explore the Potential Toxicity Mechanism of Metformin Chlorination Byproducts in Drinking Water.
Zhang GH; Liu H; Liu MH; Liu YC; Wang JQ; Wang Y; Wang X; Xiang Z; Liu W
Comb Chem High Throughput Screen; 2024; 27(1):101-117. PubMed ID: 37170985
[TBL] [Abstract] [Full Text] [Related]
20. Enrichment of
Yang X; Yang Y; Zhao L; Chen L; Wang J; Yan L; Ma J
Anticancer Agents Med Chem; 2023; 23(14):1689-1696. PubMed ID: 37151056
[TBL] [Abstract] [Full Text] [Related]
[Next]
